ALDX:NSD-Aldeyra Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.57

Change

0.00 (0.00)%

Market Cap

USD 0.50B

Volume

1.71M

Avg Analyst Target

USD 23.50 (+174.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts. Address: 131 Hartwell Avenue, Lexington, MA, United States, 02421

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD173.59B 50.81 42.70
BNTX BioNTech SE

N/A

USD87.11B 19.76 15.10
REGN Regeneron Pharmaceuticals Inc

N/A

USD69.72B 11.77 9.07
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.85B 24.83 16.64
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD37.67B N/A N/A
SGEN Seagen Inc

N/A

USD28.42B 48.74 37.66
GMAB Genmab A/S

N/A

USD27.66B 70.01 8.47
RPRX Royalty Pharma plc

N/A

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.62B N/A N/A

ETFs Containing ALDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.93% 76% C 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.93% 76% C 72% C-
Trailing 12 Months  
Capital Gain 15.34% 63% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.34% 63% D 38% F
Trailing 5 Years  
Capital Gain 24.75% 59% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.75% 59% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 39.85% 69% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.85% 69% D+ 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 95.46% 29% F 17% F
Risk Adjusted Return 41.75% 68% D+ 58% F
Market Capitalization 0.50B 58% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.12 75% C 59% F
Price / Cash Flow Ratio -13.23 65% D 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.39% 76% C 35% F
Return on Invested Capital -49.83% 48% F 17% F
Return on Assets -16.50% 72% C- 22% F
Debt to Equity Ratio 19.21% 42% F 60% D-
Technical Ratios  
Short Ratio 9.60 23% F 12% F
Short Percent 10.33% 22% F 16% F
Beta 1.70 31% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector